Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drug Conjugates Link Merck And Ambrx

by Michael McCoy
June 25, 2012 | A version of this story appeared in Volume 90, Issue 26

Merck & Co. and Ambrx will collaborate on the design and development of antibody-drug conjugates based on Ambrx’ site-specific conjugation technology. San Diego-based Ambrx is one of several biotech firms with technology to control where small-molecule cytotoxins can be attached to tumor-targeting antibodies (C&EN, June 18, page 12). Ambrx will receive an up-front payment of $15 million and is eligible for milestone payments of up to $288 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.